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Abstract:   
This study explored the possibility that upregulation of Hypoxia Inducible 
Factor-1 (Hif-1)-responsive genes in Human Umbilical Vein Endothelial Cells 
(HUVEC) would promote and stabilize HUVEC formation into inchoate vascular 
beds within artificial collagen gels.  This experiment was designed to explore the 
above possibility by sub-cloning Hif-1α, the related chimeric construct Hif-1α/VP16, 
and the marker gene dsRed into retroviral expression vectors, producing retroviral 
vectors containing these genes, and stably transducing HUVEC using these 
retroviruses.  Transduced HUVEC were to be observed in cell culture as well as after 
implantation into artificial collagen gels that have previously supported vascular bed 
formation by HUVEC.  Our results show, preliminarily, that HUVEC transduced with 
Hif-1α/VP16 go into cell-cycle arrest.  Attempts to transduce HUVEC with Hif-1α 
failed to achieve high enough transduction efficiency to determine the cells’ 
angiogenic potential.  This study concluded that more experiments need to be 
conducted to better characterize the effects of hypoxia-responsive gene upregulation 
in controlling HUVEC angiogenesis and cell-cycle signaling and that straightforward 
transduction of HUVEC by Hif-1α/VP16 is probably not sufficient, in itself, to 
induce in vitro vascular bed formation.  
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Hypoxia-inducible factor 1 (Hif-1) is a transcription factor primarily 
responsible for regulating the cellular response to hypoxia.(1)  Hif-1 affects the 
expression of numerous genes involved in nutrient delivery, extracellular matrix 
formation, the glycolytic pathway,(2) and cell survival.  In the context of its ability to 
govern the above processes, Hif-1 represents a potent tool for possible gene 
therapeutic manipulation in the treatment of several disease processes that are either 
constituted by or related to pathologic changes of the vasculature.  Upregulation of 
angiogenesis offers a potential therapy for several conditions including chronic 
cardiac ischemia and peripheral vascular disease.  Downregulation of angiogenesis 
offers a potentially important avenue for the treatment of a variety of tumors and 
other diseases associated with vascular proliferation.  More specific to the present 
study, Hif-1’s position as a transcription factor involved in regulating angiogenesis 
and the cell-cycle indicates that Hif-1 manipulation may also have important 
applications to tissue engineering, specifically in promoting the formation of viable 
vascular beds by endothelial cells.(3)  
 
The potential relevance of manipulation of angiogenesis for the treatment of 
human disease: 
The prospect of a harnessing control of angiogenesis to treat disease has broad 
appeal in a variety of clinical situations.  As mentioned above, upregulation of 
angiogenesis would have particular relevance for a person suffering the effects of 
chronic coronary ischemia or peripheral vascular disease.  The possibility that tissues 
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could be revascularized via upregulation of angiogenesis rather than via surgically 
delivered vascular grafts represents a potentially revolutionary advance in the 
treatment of these disorders.  
Regarding upregulation of angiogenesis in humans, currently, results of phase 
II or III clinical trials of therapeutic angiogenesis in humans have shown some 
promising results.  Adenovirus-mediated Vascular Endothelial Growth Factor 
(VEGF)121 and VEGF165 as well as Fibroblast Growth Factor-4 (FGF-4) have been 
used with some signs of success in the treatment of both coronary artery disease and 
peripheral vascular disease.(4)  Specifically, while adenovirus-mediatedVEGF 
transfection during Percutaneous Transluminal Coronay Angiography (PTCA) and 
stenting did not reduce clinical restenosis rates or extent of restenosis (defined as 
minimal lumen diameter), it did result in improved myocardial perfusion (as 
measured by perfusion at rest minus perfusion during adenosine administration).(5, 6)  
The improved perfusion, however, was not associated with any improvement in 
functional status.  A randomized, double-blind, placebo-controlled trial of adenovirus 
mediated FGF-4 for chronic coronary ischemia showed more clinically significant 
results.  In particular, at eight week follow-up of this cohort of 52 patients, freedom 
from angina was observed in 30% of the treatment group versus 13% of the placebo 
group, and 43% of the treatment group was not taking nitrates versus 17% of the 
placebo group.(7) 
In a randomized double-blind placebo-controlled trial of VEGF administration 
for limb ischemia in 36 patients, digital subtraction angiography showed statistically 
significant increases in the vascularity of limbs treated with VEGF in comparison to 
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placebo.  However, similar to the coronary VEGF trial mentioned above,(6) no 
clinically significant difference in limb perfusion was detected.  Specifically, Ankle-
Brachial Index and mean Rutherford class were similarly improved in both placebo 
and treatment groups.(8)  
The discordance between statistically significant improvements in laboratory 
endpoints of vascular status and lack of clinical improvement in some of the above 
trials may be due to the fact that induction of angiogenesis, to the extent that it occurs 
in these trials, is most likely happening at the level of the microcirculation.  
According to Poiseuille’s Law, resistance decreases (and hence flow increases) 
proportionally to the fourth power of the radius of a vessel.  Increasing the numbers 
of tiny capillaries in an ischemic region may therefore do little to increase actual 
blood flow significantly.  It has been estimated that 42,000 capillaries of 7-μm 
diameter would be needed to provide the equivalent blood flow found in one small 
artery of 100-μm in diameter.(4)  Hence, although initial trials have shown 
promise,(9) the possibility that gene therapeutic upregulation of angiogenesis will 
reach the level of common clinical practice as the sole or primary treatment for 
ischemic disorders may await the development of methods to engineer larger caliber 
vasculature.  
While the above discussion has illustrated the limited success of efforts to 
“turn on” the angiogenic switch, efforts to turn the angiogenic switch off have made 
further inroads into the realm of standard clinical practice.  The ability to inhibit 
angiogenesis has the potential of great clinical utility.  In the field of oncology, 
downregulation of angiogenesis has been recognized as a potent therapeutic target at 
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least since Judah Folkman and others first isolated soluble angiogenic factors from 
tumors and postulated the necessity of angiogenesis for tumor growth.(10, 11)  
Beyond the laboratory, minimally invasive treatment modalities leading to regression 
of tumors by starving them of their blood supply have already entered clinical 
practice.  One notable example of this technology is the VEGF monoclonal antibody 
bevasizumab (Avastin®), which has shown convincing benefits in the treatment of 
colorectal cancer and has shown promise in the treatment of renal cell cancer, non-
small cell lung cancer, pancreatic cancer and metastatic breast cancer.(12)  The broad 
variety of cancers susceptible to this single treatment modality points to the near 
universal utility that control of angiogenesis would afford the oncologist.  
The effort to block vascular proliferation has applications beyond oncology.  
For example, the ability to induce regression of proliferative diabetic retinopathy, 
macular degeneration, or a benign hemangioma via administration of soluble 
angiogenesis inhibitors or by altering the genome of the pathological vasculature has 
obvious appeal. 
 
A brief history of gene therapy in the treatment of human disease and the need 
for improved delivery systems: 
One of the earliest trials that provided a foundation for using gene therapy for 
the treatment of human disease occurred in 1987 when Hershfield, et al. had limited 
success in treating children with Severe Combined Immuno-Deficiency (SCID) 
secondary to Adenosine Deaminase (ADA) deficiency with enzyme replacement via 
administration of bovine ADA to peripheral lymphocytes.(13)  Later work by Kohn, 
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et al. improved on this method by using retroviral-mediated gene therapy to stably 
transduce lymphocytic precursors, rather than using transient non-genomic alteration 
of mature immune cells.  Kohn, et al. successfully harvested CD34+ lymphocyte 
progenitor cells from the umbilical blood of 3 SCID babies and then transduced those 
cells with full copies of the human Adenosine Deaminase gene before autologous 
reimplantation into the peripheral blood of the three patients.(14)  His group 
demonstrated the proliferation of the transduced cells and a corresponding long 
lasting therapeutic benefit to these patients.(15)   
The success of these trials was promising and led to a proliferation of clinical 
studies of gene therapy.  However, the news in 1999 that an 18-year-old subject 
enrolled in a gene therapy trial at the University of Pennsylvania died four days after 
adenovirus-mediated gene therapy for ornithine transcarbamylase deficiency 
highlighted the potential danger and experimental nature of the technique.(16)  In 
2002, there was further cause for caution in gene therapy trials after two patients in a 
trial to treat X-linked SCID (independent from the Kohn, et al. trials mentioned 
above) were found to have contracted a lymphoproliferative disorder similar to 
leukemia.(17)  Unlike the adenovirus-mediated trial at the University of 
Pennsylvania, the SCID trial used a retroviral vehicle for delivery and stable 
expression of the desired gene.  While it was known that retroviral insertion into the 
genome could potentially be oncogenic, it was thought that such events would be 
exceedingly rare, requiring that gene insertion occur at one of several particular 
points in the genome.  The fact that 2 out of 10 patients developed a leukemia-like 
disorder demonstrated that the scientific understanding of the implications of 
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manipulating the genome remained stubbornly rudimentary.  This second story of the 
dangers of gene therapy was, along with the U Penn tragedy, picked up by the 
popular press(18) and highlighted the need for further work on safe and effective 
delivery methods for gene therapeutic agents.  The X-linked SCID patients developed 
problems years after treatment, demonstrating that studies of safety would require 
follow-up both in the immediate post-treatment period as well as years into the future.  
Despite the above well-publicized setbacks for gene therapy, the broader 
picture shows that scientific interest in gene therapy remains robust, and it continues 
to hold much promise as a potential treatment modality.  As evidence for this claim, a 
recent search of the clinicaltrials.gov database using “gene therapy” as a search term 
in the “treatment” field resulted in a list of 68 registered trials that were recently in 
the process of actively recruiting study subjects.(19)    
In addition, it is worth noting that the desire for safe and effective delivery 
systems points to one potential benefit of the artificial vascular bed project described 
herein.  If gene therapeutic manipulations can succeed in creating viable vascular 
beds, these artificial tissues could potentially serve as a removable nexus for delivery 
of soluble factors via genetically modified cells within the artificial vascular beds.  By 
their susceptibility to minimally invasive monitoring and their ability to be removed if 
necessary, such vascular beds could potentially increase the safety of a significant 
subset of gene therapies. 
Having briefly reviewed the clinical potential and current usage of angiogenic 
alteration as well as some of the recent history of gene therapy, I will now return to 
the biological basis for the present study’s effort to alter Hif-1α specifically, and 
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hypoxia-inducible gene expression in general, for the creation of artificial 
vasculature. 
 
The structure of Hif-1 and its regulation in cells: 
In its transcriptionally active form, Hif-1 is  a heterodimer(20) composed of a 
hypoxia-inducible Hif-1α subunit and a β subunit comprised of the constitutively  
expressed aryl hydrocarbon receptor nuclear translocator (ARNT).(20, 21)  While the 
alpha subunit is unique to Hif-1, the beta subunit is active in a number of pathways 
through its ability dimerize with a number of the bHLH-PAS family of proteins.(20, 
21)   After dimerizing, Hif-1 controls gene transciption by binding to hypoxia 
response elements (HREs) in the promoters of target genes containing the core 
sequence 5’-CGTG-3’.(21)  Genes containing HREs are numerous and include 
vascular endothelial growth factor (VEGF), erythropoietin, glucose transporter-1 
(GLUT-1), and several glycolytic enzymes.(22)  Teleologically, a cell encountering 
hypoxia might be expected to upregulate these very genes as it attempted to increase 
its blood supply, increase available glucose, and switch from oxygen-dependent  
oxidative phosphorylation to anaerobic glycolysis for energy. 
According to the current model, regulation of the action of Hif-1 occurs 
primarily though the control of post-translational ubiquitinylation and subsequent 
degradation of Hif-1α.(23)  In normoxic conditions, Hif-1α is constitutively 
expressed and then quickly ubiquitinylated and broken down.  This breakdown is 
mediated by the action of elongin prolyl hydroxylases which hydroxylate two proline 
residues of Hif-1α.only under normoxic conditions.(23)  With Hif-1α in its 
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hydroxylated state, Von Hippel Lindau (VHL) protein organizes a complex leading to 
activation of the E3 ubiquitin ligase which ubiquitinylates Hif-1α, targeting it for 
degradation by a proteosome.(22),(24)  In hypoxic conditions, Hif-1α remains 
unhydroxylated and hence avoids ubiquitinylation by VHL, remaining free to 
dimerize with ARNT into its active DNA-binding form.  The degradation process has 
been shown to be VHL-dependent, so that in the absence of VHL, even after Hif-1α 
is hydroxylated, it remains stable and available for dimerization.(25)  The loss of Hif-
1α ubiquitinylation by VHL is believed to be responsible for the highly vascular 
nature of tumors in which VHL is inactivated.(23)  This phenomenon of VHL-loss-
associated angiogenesis is well-known in the context of the Von-Hippel Lindau 
syndrome in which genetic errors in VHL are associated with retinal and central 
nervous system hemangiomas.(26) 
 
Hif-1 and its role in Apoptosis and Cell-Cycle Regulation: 
While Hif-1 is clearly a promoter of angiogenesis, its effects on apoptosis and 
the cell cycle are less well-defined.   Hif-1 has been associated both with pro and anti-
apoptotic processes.(22)  For example, hypoxia increases the Hif-1-mediated 
expression of Nip3 which is a pro-apoptotic gene.(22)  Hypoxia also induces 
stabilization of p53 which results in increased expression of several pro-apoptotic 
genes, an effect not seen in Hif-1α deficient cells.(22)  On the other side of the coin, 
upregulated expression of Hif-1α has been shown to induce resistance to apoptosis in 
pancreatic cancer cells.(27)  In another experiment, hypoxia was shown to confer 
protection from radiation-induced apoptosis perhaps by elevating levels of bcl-2 as 
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well as altering intracellular trafficking of the pro-apoptotic bax protein.(28)  Further 
evidence of Hif-1’s role as an anti-apoptotic factor comes from the observation that 
iron chelators confer protection on cortical neuron cultures from oxidative stress-
induced apoptosis and that this effect is associated with increased DNA binding of 
Hif-1.(29)  In sum, Hif-1 appears to alter several apoptosis-associated genes, and 
whether its ultimate effect is toward or away from apoptosis probably depends on the 
specific cell type and cell environment in which it is upregulated. 
Regarding cell-cycle regulation, conflicting data indicate that Hif-1’s role in 
inhibiting cell proliferation needs further delineation.  In general, hypoxia is known to 
induce cell-cycle arrest,(30) with different levels of hypoxia required to arrest cells in 
at least 3 different points in the cell cycle.(31)  Extreme hypoxia will arrest cells in S-
phase and is associated with a pRetinoblastoma (pRB)-independent decrease in cyclin 
A protein levels.(31)  In G1, at least two different points of hypoxia-induced arrest 
have been characterized .(31)   Transfection of HUVEC with Hif-1α has been 
associated with increased expression of p21, decreases in Bcl-2 expression, and 
subsequent cell-cycle arrest in G1.(32)  In murine embryonic fibroblasts and splenic 
B-lymphocytes, exposure to hypoxia leads to arrest in G1 through a Hif-1α-
dependent  pathway.(30)  In contrast, Gardner, et al. found that Hif-1α-null 
embryonic stem cells arrested in G1 in a similar fashion to Hif-1α-competent stem 
cells.(33)  Elucidating the precise contribution of Hif-1α  in regulating the cell-cycle  
will likely await the better characterization of several arrest-points within G1 in 
which Hif-1α will play differing roles.  Moreover, Hif-1s role at each of these arrest 
points may also vary among different cell lineages.  




Hif-1-responsive genes as a potential target of manipulation in the creation of 
artificial vascular beds by endothelial cells: 
Given Hif-1’s well-established role in angiogenesis, its potential role as an 
anti-apoptotic agent, and its ambiguous effects on cell proliferation, the present study 
attempted to assess the possibility that upregulation of Hif-1-responsive genes would 
promote and stabilize artificial vascular bed formation by endothelial cells.  
Schechner, et al.(3) have succeeded in getting human umbilical vein endothelial cells 
(HUVEC) to form tubes in a three-dimensional collagen-fibronectin gel, which upon 
implantation into immuno-compromised mice, form complex microvessels lined by 
human endothelium.  They have observed in their experiments that the HUVEC in 
these gels, if not implanted into mice, apoptose after 24 hours.  Overcoming this 
tendency of HUVEC to apoptose has been a major focus of attempts at creating 
artificial vascular beds.(34, 35)  Schechner, et al. were able to delay HUVEC 
apoptotis in vitro for over 7 days by retroviral transduction of HUVEC with a gene 
expressing caspase-resistant Bcl-2.(3)  Such transduced cells have not only lived 
longer in vitro, but when implanted subcutaneously into immuno-compromised mice, 
have been shown to organize by 60 days into HUVEC-lined multi-layered 
microvessels invested with smooth muscle which anastomose into the native mouse 
circulation.    
Other investigators have tried anti-apoptotic agents other than Bcl-2 to aid in 
HUVEC angiogenesis.  One successful strategy at inducing HUVEC to undergo 
inchoate angiogenesis in vitro has employed the use of oncogenic phorbol esters, 
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specifically phorbol myrestate acetate (PMA) which both prevents HUVEC apoptosis 
and induces HUVEC invasion into artificial collagen gels.(34, 35)   
Though specific alteration of the expression of Hif-1-responsive genes in 
HUVEC has not been attempted previously in the effort to create artificial vascular 
beds, there are reasons to believe that such experiments may prove fruitful. Hif-1, as 
mentioned previously, is a known promoter of VEGF expression, and VEGF has been 
used in HUVEC angiogenesis experiments with some positive results.  Although 
VEGF alone has not induced angiogenesis by endothelial cells in artificial collagen 
gels, it has shown a role in stabilizing inchoate endothelial tubule formation.  When 
HUVEC are exposed to VEGF without concomitant exposure to PMA, they fail to 
penetrate and proliferate in artificial collagen beds, however VEGF has been shown 
to prevent regression of endothelial tubules after they have been formed in the 
presence of PMA.(35)   
Beyond its upregulation of VEGF, Hif-1 may also prove important in 
promoting HUVEC tubule formation through a mechanism similar to that of PMA.  
The mechanism by which PMA induces tubule formation by HUVEC is not fully 
known, however one possibility is that it acts in part through upregulation of Ap-1, a 
transcription factor which is activated both by phorbol esters and hypoxia.(36)  
Multiple possible Ap-1 binding sites have been identified in the promoter sequence of 
Hif-1α,(36) and it is possible that phorbol esters may ultimately  promote HUVEC 
tubule formation through downstream  upregulation of Hif-1α via Ap-1.  
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Strategies for artificially upregulating Hif-1 activity and the expression of Hif-1-
responsive genes: 
Several strategies have been successful in the effort to artificially induce 
transcription of Hif-1-responsive genes.   Perhaps the most straightforward method 
for upregulating Hif-1-responsive gene expression is to expose cells artificially to 
hypoxia which results in almost immediate increases in Hif-1 DNA binding.(37)  
Likewise, restoration of normoxic conditions results in rapid dissociation of Hif-1 
from its binding sites, with half-lives for both association and dissociation of under 
one minute.(37)  Although hypoxia is quite effective in inducing Hif-1-responsive 
genes, it is clearly an impractical strategy for long-term induction of such genes in 
cells outside of tightly regulated cell culture conditions.  Desferrioxamine and Cobalt 
Chloride have also been shown to upregulate Hif-1 DNA binding with kinetics 
similar to those of hypoxia,(38) however neither is compatible with long-term in vivo 
upregulation of Hif-1-responsive genes.   
Hif-1-responsive genes have also been successfully upregulated by gene 
therapeutic manipulation of cellular levels of Hif-1α.(39)  Given that Hif-1 activity is 
primarily regulated by post-translational destruction of Hif-1α, the fact that 
increasing cellular Hif-1α levels results in alteration of Hif-1-responsive gene 
expression was not obvious.  It might have been expected that increased Hif-1α 
expression would have been cancelled-out by increased destruction of Hif-1α, leading 
to no change in Hif-1-responsive transcriptional activity.  With acute increases in Hif-
1α protein concentration, however, the Hif-1-responsive genes VEGF and GLUT-1 
have been shown to be upregulated, indicating that the Hif-1α degradation pathway 
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cannot immediately compensate for elevated Hif-1α levels.  Nevertheless, there is 
evidence to suggest that a feedback upregulation of Hif-1α degradation may happen 
in response to elevated Hif-1α levels.  Cells that were induced to produce an over 
100-fold increase in Hif-1α expression through a Tetracycline-controlled induction 
method were found after 1 week to have decreasing levels of Hif-1α expression 
despite continued exposure to doxycycline-free media.(39)  Such cellular behavior 
indicates that the upregulation of Hif-1-responsive genes obtained by artificially 
raising Hif-1α levels may ultimately be a transient phenomenon. 
An alternative strategy, which may lead to a more sustained upregulation of 
Hif-1-responsive genes, has been to employ the use of artificial transcription factors.  
One such transcription factor with demonstrated success is the chimeric Hif-1α/VP16 
(Genzyme).  Hif-1α/VP16 encodes a hybrid protein composed of the DNA-binding 
and dimerization domains of Hif-1α protein and the trans-activation domain of the 
Herpes Simplex Virus (HSV).(40)  Direct intramuscular gene transfer of Hif-
1α/VP16 into ischemic rabbit hind-limbs has resulted in therapeutic levels of 
angiogenic response.(40) In a porcine model of cardiac ischemia, adenovirus-
mediated transduction of Hif-1α/VP16 led to increased myocardial perfusion and 
increased left ventricular function, an effect not seen with Hif-1α plasmid 
delivery.(41) The specific pattern of gene upregulation after transfection with Hif-
1α/VP16 is related to, but not identical with, the pattern induced by hypoxia.  Gene 
expression patterns following Hif-1α/VP16 transfection have been studied in cardiac 
myocytes,(42) and several known Hif-1-responsive genes including VEGF, Glut-1, 
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insulin-like growth factor binding protein 3, and several glycolytic enzymes have 
been upregulated. However, adenovirus-mediated transfection of myocytes with Hif-
1α/VP16 also resulted in upregulation of several genes not previously known to be 
regulated by hypoxia, HIF-1, or adenovirus infection including plasminogen activator 
inhibitor 1 (PAI1) and endothelial differentiation factor 1.   
The gene-expression pattern of Hif-1α/VP16 makes it potentially even more 
promising than wild Hif-1α for inducing HUVEC angiogenesis.  Insulin-like growth 
factor binding proteins control the activity of insulin-like growth factor which when 
upregulated has been associated with VEGF-dependent neovascularization  in 
diabetic retinopathy.(43)  In addition, the fact that Hif-1α/VP16 upregulates PAI1 
may be especially promising since PAI1 has been implicated in the control of 
endothelial cell migration and tube formation in vitro as well as of in vivo tumor 
invasion and angiogenesis.(42, 44, 45)  Beyond its potentially superior gene-
induction profile for angiogenesis, Hif-1α/VP16 may also have more benign effects 
on apoptosis than wild Hif-1α.  As above, Hif-1 has been implicated in the induction 
of apoptosis via affects on p53 and bcl-2.(42, 46)  In cardiac myocyte transfection, 
however, Hif-1α/VP16 was found to upregulate the pro-survival genes Nip-3 and 
TNF-α, with no observed increase in apoptotic activity.(42)  While Hif-1-responsive 
genes have been implicated in both pro and anti-apoptotic processes, it is not known 
to what extent Hif-1α or Hif-/VP16 affect apoptosis and cell-cycling in HUVEC. 
 
The practical appeal of upregulating Hif-1α or employing Hif-1α/VP16 to induce 
HUVEC angiogenesis: 
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The possibility that Hif-1-responsive gene manipulation might both delay 
apoptosis in HUVEC as it has done in other cell lines, as well as stabilize and 
promote inchoate vascular bed formation through upregulation of VEGF and other 
angiogenic genes makes it a promising strategy for inducing in vitro HUVEC 
angiogenesis.  If such an approach were to work, not only would it facilitate the 
development of artificial vasculature, but it might make such artificial tissue more 
readily acceptable for use in human subjects by avoiding the use of known oncogenic 
alterations to HUVEC.  If the implantation of artificial vascular beds into human 
subjects has any hope of one day playing a therapeutic role in human disease, 
avoiding the direct alteration of Bcl-2, the use of phorbol esters, or other oncogenic 
alterations would certainly be preferable.(47)  Efforts in this regard have recently 
found success through co-implantation of endothelial cells with mesenchymal 
precursor cells.(47)  In any case, observations of the effects that upregulation of Hif-
1-responsive genes have on the behavior of HUVEC may have important implications 
both for tissue engineering as well as the understanding of Hif-1’s role in endothelial 
cell biology in general. 
 
Methods: 
In order to test the hypothesis that upregulation of Hif-1-responsive genes 
would induce HUVEC angiogenesis, we sub-cloned three constructs for retroviral-
mediated transduction into HUVEC.  The first construct consisted of human Hif-1α 
cDNA which we sub-cloned into pLNCX2 (Clontech), a retroviral packaging plasmid 
capable of producing high-titre, replication-incompetent retroviruses.  The second 
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construct consisted of Hif-1α/VP16 cDNA (Genzyme) which we sub-cloned into 
pLNCX2, and the third construct was dsRed (Clontech), a gene coding for a protein 
exhibiting red phosphorescence under ultraviolet light, which we sub-cloned into 
pLNCX2.  dsRed was to be used as an easily identifiable marker for transduction 
success in parallel with other transductions. 
 
Sub-Cloning human Hif-1α cDNA into the viral packaging plasmid pLNCX2: 
 Plasmid containing human wild Hif-1α cDNA within 
pBSK(Bluescript/Stratagene) was obtained from Reed Hickey (Giordano Lab, Yale 
University School of Medicine).  The Hif-1α gene was removed from pBSK using a 
5’ EcoRV/NotI 3’ restriction digest, and an appropriately-sized 3.6 Kbp fragment was 
gel isolated.  Preparation of pLNCX2 was accomplished first by cutting with HindIII 
restriction digest at the unique HindIII site in the multiple-cloning site (MCS) of 
pLNCX2.  This cut plasmid was then blunt-ended using Klenow Fragment 
exonuclease (New England Biolabs) in EcoPol Buffer.  This blunt-ending was meant 
to correspond to the blunt-cut EcoRV site on the Hif-1α fragment.  Blunted 
pLNCX2-HindIII digest was then cut at a single MCS point with a NotI restriction 
digest, corresponding to the 3’ Not I cut on the Hif-1α fragment.  The 6.1 Kbp 
fragment from this Not I digest was gel isolated.  Ligation of Hif-1α into pLNCX2 
was then attempted after treatment of pLNCX2 with Shrimp Alkaline Phosphatase 
(Roche).   
 After the attempted ligation, we attempted to transform a JM-109 strain of e. 
coli with  the sub-cloned Hif-1α/pLNCX2 via heat-shock.  JM-109 were then plated 
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on ampicillin-containing media to select for pLNCX2-containing e.coli (pLNCX2 
contains an ampicillin-resistance gene).  10 ampilcillin-resistant colonies were picked 
and mini-prepped.   
To check if the correct plasmid containing the full Hif-1α/pLNCX2 construct 
was present, DNA from each of these 10 mini-prepped colonies was cut with 
BglII/SalI digest and run on a gel.  The expected fragment sizes would be 127bp, 
652bp, 2.9Kbp, and 6Kbp which corresponded with the gel for 7 of the colonies, one 
of which was then maxi-prepped (see figure 1 in appendix).  
 
Sub-Cloning Hif-1αVP16 cDNA into the viral packaging plasmid pLNCX2: 
 Plasmid containing the chimeric Hif-1α/VP16 cDNA within pBSK was 
obtained from Reed Hickey (Giordano Lab, Yale Universtiy School of Medicine).  
The plasmid was cut with ClaI restriction digest and then blunt-ended using Klenow 
Fragment exonuclease  followed by another cut with a Not I restriction digest, leading 
to a 1.5 Kbp Hif-1α/VP16 fragment with 5’ blunt end and 3’Not I-cut restriction site.  
This 1.5Kbp Hif-1α/VP16 fragment was gel isolated.  As in the above section, 
pLNCX2 with 5’ blunt end and 3’Not I cut restriction site was made.  As above, 
ligation of Hif-1α/VP16 into pLNCX2 was attempted after treatment of pLNCX2 
with Shrimp Alkaline Phosphatase (Roche). 
  After the attempted ligation, a JM-109 strain of e. coli was transformed with  
the sub-cloned Hif-1α/VP16/pLNCX2 via heat-shock.  JM-109 were then plated on 
ampicillin-containing media to select for plasmid-containing e.coli.  6 ampilcillin-
resistant colonies were picked and mini-prepped. 
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 To check if the correct plasmid containing the full Hif-1αVP16/pLNCX2 
construct was present, DNA from these 6 mini-prepped colonies was cut with AvaI 
restriction digest and run on a gel.  The expected visible fragment sizes would be 
600bp, 1.2Kbp, 2.5Kbp, and 2.9Kbp which corresponded with the gel for 4 of the 6 
colonies, one of which was then maxi-prepped (see figure 2 in appendix). 
 
Sub-Cloning of dsRed cDNA into the viral packaging plasmid pLNCX2: 
 Plasmid containing the dsRed cDNA was obtained from Reed Hickey 
(Giordano Lab, Yale University School of Medicine).  The plasmid was cut with 5’ 
HindIII/NotI 3’ restriction digest and the corresponding 700bp dsRed fragment was 
gel isolated.  Similarly, pLNCX2 was cut with 5’ HindIII/NotI 3’ restriction digest 
and the corresponding 6.1 Kbp fragment was gel isolated.  As above,  ligation of 
dsRed into pLNCX2 was attempted after treatment of pLNCX2 with Shrimp Alkaline 
Phosphatase (Roche). 
 As above, after the attempted ligation, a JM-109 strain of e. coli was 
transformed with  the sub-cloned dsRed/pLNCX2 via heat-shock.  JM-109 were then 
plated on ampicillin-containing media to select for pLNCX2-containing e.coli.  10 
ampilcillin-resistant colonies were picked and mini-prepped. 
 To check if the correct plasmid containing the full dsRed/pLNCX2 construct 
was present, DNA from each of these 10 mini-prepped colonies was cut with 
HindIII/NotI restriction digest and run on a gel.  The expected visible fragment sizes 
would be 6.1Kbp and 700bp  which corresponded with the gel for all 10 colonies, one 
of which was then maxi-prepped (see figure 3 in appendix). 




Transfection of the packaging cell line and determination of retroviral titre:   
 Retropack PT67 packaging cells were obtained from BD Biosciences 
(www.bdbiosciences.com) and grown in cell culture using DMEM (Gibco) 
supplemented with 10% fetal bovine serum, 1% glutamine, and 1% 
penicillin/streptomycin solution.  24 hourse before transfection, packaging cells were 
plated at approximately  60% confluency on 60mm plates.  Transfection with plasmid 
DNA containing dsRed was accomplished by mixing 16mcg of dsRed in 3mL of 
DMEM along with 40mcL Lipofectamine 2000 (Invitrogen), and after 20 minutes of 
incubation, pipetting the mixture onto PT67 cells. 
 Eighteen hours post-tranfection, culture medium was removed, and packaging 
cells were washed with phosphate buffered saline twice.  Cells were then plated with 
selection medium containing 100mcg/mL of geneticin (pLNCX2 contains a neomycin 
resistance gene).  After 7 days, surviving cells were examined under ultraviolet light 
and glowed red as would be expected for dsRed-containing cells.  Retrovirus-
containing media was harvested every 24 hours.  To assess retroviral titre, NIH-3T3 
cells were plated in six well plates to a density of approximately 105 cells per well 
with medium as above.  Six 10-fold serial dilutions of retrovirus-containing medium 
were made, and added to 3T3 plates.  48 hours after attempted transduction, 3T3s 
were examined under ultraviolet light. No cells beyond the 10-4 dilution glowed red.  
Because a density of at least 106 virions/mL was desired, the above transduction was 
attempted with the addition of 4mg/mL of polybrene, a polycation capable of 
diminishing electro-static repulsion between cells and virions.  However, no cells 
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were successfully transduced after numerous attempts, indicting either that virions 
had lost their infectivity or that polybrene was interfering in the process.  Multiple 
repeat attempts at re-transfection of packaging cells and retrovirus production proved 
unsuccessful.  Because 104 infective virions/mL was considered too low for 
transduction of HUVEC, and because the viability of these virions was questionable 
after subsequent attempts failed to observe infectivity, David Enis of the Schechner 
Lab, Yale University School of Medicine, re-attemtpted transfection of a different 
retroviral packaging cell line with our three constructs.     
 For the further attempts at retroviral production, the GP2-293 packaging cell 
line (Clontech) was used.  This packaging cell line requires co-transfection with 
pVSV-G, a plasmid expressing VSV-G from the cytomegalovirus promoter.   VSV-G 
is toxic to the packaging cells, so retrovirus particles must be transfected with pVSV-
G simultaneously with the desired genes, and retroviral harvesting must be done 
shortly after transfection.  Accordingly, GP2-293 cells were grown in cell culture 
using DMEM (Gibco) supplemented with 10% fetal bovine serum, 1% glutamine, 
and 1% penicillin/streptomycin solution.  24 hourse before transfection, packaging 
cells were plated at approximately  60% confluency on 60mm plates.  Dave Enis 
accomplished transfection with the above pLNCX2 constructs containing dsRed, Hif-
1α, and Hif-1α/VP16 and pVSV-G by mixing equal amounts of each plasmid with 
pVSV-G and pipetting the three mixtures over plated GP-2 cells.  Ninety hours post-
transfection, retrovirus-containing supernatant was harvested and added to cultured 
HUVEC to which Geneticin was added to select for transduced cells. 
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HUVEC Cell Culture and Creation of Artificial Collagen Gels:   
David Enis of the Schechner laboratory maintained and transduced HUVEC in 
cell culture.  Isolation and culture of HUVEC has been described elsewhere(48), 
however briefly, HUVEC can be harvested from flushed umbilical veins via use of 
collagenase solution and cutured in Medium 199 containing 15mM HEPES organic 
buffer.(48)  Had the transduction produced a stable line of replicating HUVEC, 
collagen gels would have been formed as described elsewhere.(3)  Briefly, as 
described by Schechner et al., HUVEC would be suspended in Hepes and NaHCO3 
buffered Medium 199 with rat-tail type 1 collagen (1.5 mg/ml) and human plasma 
fibronectin (90mcg/ml) and then brought to pH 7.5 with 0.1 molar HCl at 4 degrees 
Celsius. The suspended HUVEC would then be inserted into rat-tail type 1 collagen-
coated C-6 transwells and warmed to 37 degrees for collagen polymerization and then 
covered with Medium 199 supplemented with 20% FBS, 50 mcg/ml endothelial cell 
growth factor, 200 mcg/ml streptomycin and penicillin, 2mM L-Glutamine and 100 
mcg/ml heparin.(3) The above collagen-gel formation was not performed, however, 





 The majority of HUVEC in the plate transduced with dsRed glowed red when 
exposed to ultraviolet light, appearing to validate our transduction methods.  After 
exposure to Geneticin, only glowing, dsRed-containing HUVEC survived, further 
indicating the success of the transduction as well as the selection method.  Because 
the dsRed transduction was conducted in parallel with Hif-1α and Hif-1α/VP16 
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transductions, it was taken as reassurance that the latter two transduction procedures 
were also valid.  In the Hif-1α-transduced plate, however, very few of the cells 
survived exposure to Geneticin, and it was felt that transduction efficiency was 
insufficient to warrant implantation of the few remaining cells into collagen gels.  
HUVEC transduced with Hif-1α/VP16 appeared to achieve good transduction 
efficiency similar to the success of dsRed transduction, as evidenced by the majority 
of Hif-1α/VP16-transduced HUVEC surviving exposure to Geneticin.  The surviving 
Hif-1α/VP16-transduced HUVEC were observed to grow larger and stop replicating 
in cell culture shortly after selection and prior to attaining the requisite cell count for 
collagen-gel insertion trials.  Following these observations, an effort was made to 
confirm the success of HUVEC transduction with Hif1-α/VP16 by conducting 
Western Blot analysis of the transduced HUVEC using antibody to the HSV VP16 
protein.  David Enis conducted this Western Blot and, by report, confirmed the 
presence of VP16 protein in transduced HUVEC.   
 While further analysis of the Hif-1α/VP16-transduced HUVEC was felt to be 
warranted to document the gene expression pattern associated with their arrested 
replication, laboratory priorities were more focused on engineering successful 
angiogenesis, and it was not felt that the further study of these arrested cells would be 








   While additional trials of HUVEC transduction with Hif-1α and Hif-1α/VP16 
would be necessary for any firm conclusion about their effects on HUVEC behavior, 
our initial trial does not give cause for optimism that such transductions will, in 
themselves, successfully promote HUVEC in vitro tubule formation or in vivo 
angiogenesis.  If further trials continued to show arrested proliferation of Hif-
1α/VP16-transduced HUVEC, it would be helpful to document their gene-expression 
pattern as well as the stage at which they arrested.  Specifically, gene microarray 
analysis of expression patterns could be used for the former, and for the latter, flow 
cytometry has been used in previous experiments to document the stage of cell cycle 
arrest as well as signs of early apoptosis.(32) Nevertheless, while further trials and 
experiments are needed, we have several speculative theories about why HUVEC 
appeared to stop replicating after Hif-1α/VP16 transduction. 
 As was mentioned above, hypoxia’s effects on endothelial cell cycling have 
revealed conflicting data, but cell-cycle arrest has previously been associated with 
Hif-1α and is therefore not particularly surprising to see with Hif-1α/VP16.(26, 32) 
Furthermore, there are reasons beyond our own observation in this experiment to 
suspect that Hif-1α/VP16 may be more prone to cause cell-cycle arrest than Hif-1α.  
To see this, it is useful to return to the gene expression patterns seen in previous Hif-
1α/VP16 transfection experiments.  Of note, it has been observed that at least some 
Hif-1-responsive genes show intensely increased expression by Hif-1α/VP16 at rates 
far in excess of those produced by hypoxia.  Specifically, TaqMan quantitative PCR 
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analysis of Hif-1α/VP16-transfected cardiac myocytes revealed a 102-fold increase in 
VEGF expression over control myocytes as compared to a 4-fold increase from 
hypoxia alone.  Regarding VEGF induction, Hif-1α/VP16 was over 25-times more 
potent  than hypoxia alone in cardiac myocytes. It is possible that while physiologic, 
mild hypoxic signaling could induce endothelial cell proliferation, Hif-1α/VP16 may 
have mimicked HUVEC exposure to extreme hypoxia, which has been shown to 
induce cell-cycle arrest (49) as mentioned above.   
 Another observation of Hif-1α/VP16-transfected cells is that they have 
previously shown “dramatically” elevated (numeric data was not presented) levels of 
brain natriuretic peptide (BNP), a gene only “moderately” induced by hypoxia.(42)  It 
is possible that the Hif-1α/VP16-transduced HUVEC in our experiment were not 
truly quiescent.  Among other things, BNP elevation is associated with cell 
hypertrophy and has even been used as a marker for cell hypertrophy in myocyte 
studies.(50) It is possible that the Hif-1α/VP16-transduced HUVEC in our 
experiment were not entirely arrested but instead had begun a hypertrophic process. 
To assess this possibility, transduced HUVEC would need more extended observation 
than we conducted, including measurements of BNP expression.  The observation 
that they were growing larger was consistent with continued protein synthesis in the 
absence of proliferation, which could be indicative either of physiologic hypertrophy 
or with failure to replicate due to cell-cycle arrest. 
 Another possibility of why our Hif-1α/VP16-transduced HUVEC stopped 
replicating rests on the fact that retroviral transduction with any construct is bound to 
cause multiple alterations in the biology of a cell, independent of any specific process 
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related to hypoxia-inducible gene expression.  Specifically the use of the HSV VP16 
activation domain, might be particularly prone to interfere with cell-cycling.  During 
HSV infection, VP16 protein is required for immediate early transcription of viral 
proteins.  It binds with several proteins in a host cell to form a complex to induce 
transcription, and one of these host proteins is known as Host Cell Factor (HCF).(51)  
HCF is primarily a protein necessary for cell cycling, specifically it is one of a 
number of proteins necessary for the progression of cells from G1 to S phase.(52)  
Although cell cycle arrest has not previously been reported in gene therapy trials 
using chimeric constructs containing a VP16 domain, it is theoretically possible that 
in our trial, expression of VP16 protein in HUVEC interfered with the action of the 
native HCF protein and caused arrest in G1. 
 If Hif-1α/VP16 transduction is shown in repeated attempts to induce arrest in 
HUVEC, there still may be a role for this artificial transcription factor in promoting 
artificial angiogenesis.  To overcome its affects on cell cycling while still benefiting 
from upregulation of hypoxia-responsive genes, a fruitful strategy for angiogenesis 
might be to transduce endothelial or mesenchymal cells with Hif-1α/VP16 and co-
implant them with wild-type endothelial cells into artificial collagen gels.  The basic 
strategy of co-implantation of transduced cells and wild-type cells has proved fruitful 
previously in supporting angiogenesis.(47) Whatever proteins from Hif-1α/VP16 
have been responsible for previous successful efforts to promote angiogenesis could 
then act on wild-type HUVEC through paracrine affects without interfering with 
HUVEC replication directly.  Such paracrine affects could be responsible for the in 
vivo success of previous Hif-1α/VP16 angiogenesis experiments.(40)   




Assessment of the paracrine effects of HIF-1α expression in parenchymal cells 
on glucose metabolism and on the expression of adhesion complexes: 
 Germane to the above discussion, the Giordano laboratory has explored the 
possibility of paracrine effects of hypoxia-inducible gene upregulation and has 
confirmed their presence on both glucose metabolism and adhesion-molecule 
expression.  In one series of experiments, the laboratory tested the effects of 
conditioned media from Hif-1α-transduced endothelial cells on glucose uptake in 
myoblasts.  As shown below (figure 4), the conditioned media taken from plates of 
Hif-1α-transduced endothelial cells, when added to myoblasts in cell-culture, 
significantly increased glucose uptake in the myoblasts in a paracrine manner, 
establishing that there is indeed cross-talk from the endothelium to parenchymal cells 
that can effect metabolism.(53)   
Figure 4: 
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     p<0.05 for GFP vs Hif difference 
 
In other experiments, conditioned media from HIF-1α-transduced myoblasts 
was incubated with HUVEC monolayers.  By Fluorescence Activated Cell Sorting 
analysis (not shown) there was a significant increase in the expression of ICAM-1, 
VCAM, and MadCAM in response to the conditioned media.  By focused microarray 
analysis there were several endothelial adhesion molecule genes upregulated in 
response to the conditioned media.  The table below (figure 5) is an abridged list of 
these genes.  The designation on the left is the gene identity, and the number on the 
right is the fold altered relative to controls.  Positive numbers indicate upregulation, 
whereas negative numbers indicate downregulation.  For example, ICAM-1 is 
upregulated 1.65 x control; integrin alpha 1 (ITGA1) is upregulated 2.96 x over 
control.(53)  
Figure 5: 
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In addition to its implications for gene therapy, the above data have significant 
implications for the understanding of endothelial cell biology in general.  The 
endothelium, far from being simply a passive layer of boundary cells, can have 
critical effects on whole-organ and whole-organism metabolism via paracrine effects 
as well as via altered molecular transport. 














The critical effects of Hif-1α alteration on whole-organ and whole-organism 
biology: 
To further elaborate on the role of endothelial Hif-1α alteration on whole 
organ and organism biology, a mouse model was developed with cre-lox technology 
to obtain an endothelium-specific Hif-1α knockout.  Tie-2  Cre mice were crossed 
with mice in  which Exon 3 of the Hif-1α gene was flanked by loxP sites.  This cross 
resulted in viable litters of mice in which Hif-1α was deleted specifically in the 
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endothelium (Complete Hif-1α-knockout mice are not viable).  The efficiency of the 
endothelial-specific knockout deletion, as determined by quantitative PCR, was >90% 
in each isolated batch of endothelial cells evaluated by the Giordano lab.  Hif-1α was 
not deleted discernibly in other cell types tested, including cardiac muscle.(53)   
Basal glucose levels in these mice were measured with a strip-based 
commercial glucose monitoring system used by diabetics (figure 6). 
Figure 6: 
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To determine glucose uptake in vivo, tritiated 2-D glucose was injected by 
jugular vein into wild-type as well as endothelium-specific Hif-1α-knockout mice.  
Following injection, the heart (figure 7) and brain (figure 8) were harvested and 
assessed for uptake of the labeled glucose.(53) 
Figure 7: 




















































The above data on the local intra-cellular, regional inter-cellular, and 
organismal effects of Hif-1α manipulation within endothelial cells point to the 
potential relevance of gene therapeutic manipulation of Hif-1α-responsive genes.  
Such manipulation may prove therapeutic not only when specifically diseased cells 
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are targeted for treatment.  On the contrary, because of the wide-ranging effects that 
Hif-1α manipulation has, broader regions or systems might prove to cause significant 
alterations to the biology of a distant locus of pathology in response to such 
manipulation.   
Such a strategy is not entirely novel, as downregulation of angiogenesis for 
the control of tumor growth is but another manifestation of this idea.  That is, rather 
than targeting the specific cancerous cells for gene therapeutic manipulation, one can 
target the milieu in which those cells live – the surrounding blood vessels in the case 
of a tumor – and effect a cure at the adjacent pathological locus. 
 
Conclusion:    
Returning to the effort to engineer artificial vasculature, which was the 
original goal of this project, while the initial transduction trials described herein were 
not successful at inducing angiogenesis, this work suggests that there are possible 
uses of Hif-1α/VP16 and Hif-1α for alteration of endothelial cell behavior, as well as 
that of surrounding tissues.   By altering the cell-cycle and apoptosis-associated 
genes, changing expression of angiogenic factors, modifying energy metabolism, and 
affecting adhesion-molecule expression, both intracellularly and in a paracrine 
manner, hypoxia-inducible gene alteration may have a significant and potentially 
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Fig.1: BglII/SalI restriction digest 
of Hif-1α/pLNCX2 ligation.  Lanes 1, 4-8 and 10 contain the expected bands. 




Fig.2: AvaI restriction digest of 
Hif-1α/VP16/pLNCX2 ligation.  Lanes 1, 3, 4, and 6 contain the expected bands. 
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Lane 0 is a standard 1Kbp ladder. 
 
Fig. 3:  HindIII/NotI restriction digest of dsRed/pLNCX2 ligation.   
All ten lanes show the expected 6.1Kbp and 700bp fragment sizes. 
